- Baxter International (NYSE:BAX) initiated with Overweight rating and $52 (11% upside) price target by Barclays.
- Sophiris Bio (NASDAQ:SPHS) initiated with Buy rating and $8 (170% upside) price target by Roth Capital.
- C.R. Bard (NYSE:BCR) initiated with Buy rating and $235 (5% upside) price target by Evercore ISI.
- Health Insurance Innovations (NASDAQ:HIIQ) initiated with Buy rating and $9 (82% upside) price target by Lake Street Capital.
- ViewRay (NASDAQ:VRAY) initiated with Buy rating and $6 (60% upside) price target by BTIG Research.
- Aerie Pharmaceuticals (NASDAQ:AERI) initiated with Strong Buy rating and $48 (57% upside) price target by Raymond James.
- Vertex Pharmaceuticals (NASDAQ:VRTX) initiated with Market Perform rating by Raymond James.
- Mirna Therapeutics (MIRN) initiated with Buy rating and $6 (155% upside) price target by H.C. Wainwright.
- Oasmia Pharmaceutical AB (NASDAQ:OASM) initiated with Buy rating and $6 (82% upside) price target by Rodman & Renshaw.
- Gilead Sciences (NASDAQ:GILD) initiated with Buy rating and $112 (42% upside) price target by Berenberg Bank.